Dublin, March 05, 2026 (GLOBE NEWSWIRE) — The “GLP-1 Receptor Agonist Market Size, Share & Trends Analysis Report by Product (Trulicity, Wegovy, Ozempic, Mounjaro), Application (Diabetes, Obesity), Route of Administration, and Region with Growth Forecasts, 2026-2033” report has been added to ResearchAndMarkets.com’s offering.
The global GLP-1 receptor agonist market size was estimated at USD 70.08 billion in 2025 and is projected to reach USD 201.79 billion by 2033, growing at a CAGR of 12.78% from 2026 to 2033.
The launch of new glucagon-like peptide 1 (GLP-1) receptor agonist products, a robust product pipeline for both diabetes & obesity applications, and the high efficacy of these drugs are anticipated to propel market growth.
In May 2024, Innovent Biologics announced that its type 2 diabetes candidate, mazdutide, outperformed Eli Lilly’s Trulicity (dulaglutide) in a Phase III trial. The study established that mazdutide was superior in glycemic control and provided numerous cardiometabolic benefits, comprising weight loss & improvements in blood lipid levels, liver enzymes, serum uric acid, & blood pressure.
Other companies, such as Boehringer Ingelheim International GmbH, Carmot Therapeutics, Inc., D&D Pharmatech, Eli Lilly and Company (Lilly), and Hanmi Pharm. Co., Ltd, are also involved in developing new glucagon-like peptide 1 drugs. For instance, in October 2023, Carmot Therapeutics, Inc. published preliminary results from the single ascending dose (SAD) phase of an ongoing Phase 1 clinical trial for CT-996, an oral small molecule GLP-1 receptor agonist (RA) that is presently being assessed in a first-in-human clinical trial in individuals who are overweight or obese. Thus, increasing research in the field of GLP-1 receptor agonists is expected to drive market growth.
Moreover, the rising prevalence of obesity and diabetes is expected to drive the growth of the GLP-1 receptor agonist industry. The overweight and obese population is at a high risk of developing diabetes and cardiovascular illness. Worldwide obesity rates are rising, and it is widely acknowledged that this is one of the major public health issues of the present day.
According to the World Heart Federation’s global estimate, almost 2.3 billion children and adults worldwide suffer from obesity and overweight. Additionally, according to the Obesity Action Coalition (OAC), over 90% of individuals diagnosed with type 2 diabetes are either overweight or have some degree of obesity. Therefore, the rising obese and diabetes populations are driving the demand for GLP-1 receptor agonist drugs for treatment worldwide.
The high advantages associated with the use of GLP-1 drugs over other medicines, along with increasing investment in the R&D of new GLP-1 drugs, are driving market growth. Several GLP agonists have been linked to weight loss or weight neutrality, which is advantageous for people with diabetes since obesity frequently makes the disease worse.
The lowering of appetite and the delayed stomach emptying contribute to the weight loss effect. Moreover, in November 2023, Novo Nordisk announced its intention to invest approximately 16 billion Danish kroner in developing GLP-1 drugs. This is roughly equivalent to USD 2.32 billion (€2.14 billion). These initiatives are anticipated to drive the market’s growth.
Why You Should Buy This Report
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 150 |
| Forecast Period | 2025 – 2033 |
| Estimated Market Value (USD) in 2025 | $70.08 Billion |
| Forecasted Market Value (USD) by 2033 | $201.79 Billion |
| Compound Annual Growth Rate | 12.7% |
| Regions Covered | Global |
Market Dynamics
Market driver analysis
- Increasing prevalence of chronic diseases such as diabetes and obesity
- Increasing R&D activities for developing novel therapeutics
- Formulation advancements of oral GLP-1 receptor agonists
- Increasing awareness about diagnosis and treatment options for diabetes
Market restraint analysis
- Product failure
- Patent expiry of blockbuster drugs during the forecast period
GLP-1 Receptor Agonist Market Analysis Tools
- Industry Analysis – Porter’s
- PESTEL Analysis
- Pricing Analysis
- Pipeline Analysis
- Patent Expiry Analysis
Companies Featured
- Eli Lilly and Company
- Sanofi
- Novo Nordisk A/S
- AstraZeneca
Global GLP-1 Receptor Agonist Market Report Segmentation
Product Outlook (Revenue, USD Million, 2021-2033)
- Ozempic
- Trulicity
- Mounjaro
- Wegovy
- Rybelsus
- Saxenda
- Victoza
- Zepbound
- Other Products
Application Outlook (Revenue, USD Million, 2021-2033)
- Type 2 Diabetes Mellitus
- Obesity
Route of administration Outlook (Revenue, USD Million, 2021-2033)
Distribution Channel Outlook (Revenue, USD Million, 2021-2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Regional Outlook (Revenue, USD Million, 2021-2033)
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa (MEA)
For more information about this report visit https://www.researchandmarkets.com/r/9il4yp
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- GLP-1 Receptor Agonist Market
